Acute Regulation of Parathyroid Hormone by Dietary Phosphate

This study has been completed.
Sponsor:
Information provided by:
National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:
NCT00037193
First received: May 16, 2002
Last updated: June 23, 2005
Last verified: December 2003
  Purpose

Patients with end stage renal disease often have secondary hyperparathyroidism due to high phosphorus and low calcium levels in the blood. Preliminary animal studies and our initial human study indicate that the parathyroid hormone levels may change quickly based on the ingestion of phosphorus, prior to any change in the blood levels of calcium or phosphorus. This follow-up study will attempt to determine if the effect is independent of an increase in the blood glucose level. If so, this would suggest an as yet unidentified gastrointestinal receptor that mediates parathyroid hormone levels. This may affect the timing of administration and the type of phosphate binder used in treating patients with secondary hyperparathyroidism. The knowledge that parathyroid hormone levels can change acutely may also affect the recommended timing of blood samples


Condition
Secondary Hyperparathyroidism

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Acute Regulation of Parathyroid Hormone by Dietary Phosphate

Resource links provided by NLM:


Further study details as provided by National Center for Research Resources (NCRR):

Detailed Description:

This study is observational and no drugs or other interventions will be used. The population targeted in this study will be adult patients already on chronic hemodialysis with a diagnosis of secondary hyperparathyroidism. Experimental design will involve the use of a glucose clamp to maintain a constant, mild increase in blood glucose levels. Frequent, scheduled lab tests will be obtained during the period of hyperglycemia to evaluate phosphorous, calcium, and glucose levels and the relationship of any change in their values to changes in the parathyroid hormone level. The primary outcome will be to evaluate for any change in the parathyroid hormone level in the presence of hyperglycemia and to compare these results to that of our initial study

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  1. Patients 21 years of age or older
  2. Receiving treatment with hemodialysis for at least 90 days.
  3. Serum parathyroid hormone level greater than 200 pg/ml
  4. Serum phosphorus level greater than 4 mg/dl
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00037193

Locations
United States, Missouri
Washington University Medical School
St. Louis, Missouri, United States, 63110
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00037193     History of Changes
Other Study ID Numbers: NCRR-M01RR00036-0855
Study First Received: May 16, 2002
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Hyperparathyroidism
Hyperparathyroidism, Secondary
Endocrine System Diseases
Parathyroid Diseases

ClinicalTrials.gov processed this record on October 23, 2014